Hims vs Shed: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

Hims beats Shed overall, scoring 7.9/10 vs 7.8/10. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Shed for users who want fast delivery and a streamlined compounded gl.

A side-by-side look at Hims and Shed to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

Hims

#9 of 52

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership, alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.

Visit Hims

Shed

#15 of 52

7.8/10

Newer GLP-1 provider focused on speed and simplicity, fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Feature	Hims	Shed
Our Score	7.9/10	7.8/10
Starting Price	$199/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors	Users who want fast delivery and a streamlined compounded GLP-1 experience
Ranking	#9	#15
Get started	Visit Hims	Visit Shed

Pros & Cons Compared

Hims

Pros

+Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
+Polished app and web experience, among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.

Cons

−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
−Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
−Generic high-volume support, large patient base means less personalized attention than smaller competitors.

Shed

Pros

+Industry-leading delivery speed, most patients receive medication within 2-3 days of enrollment
+$199/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call, approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−The core $199 program is compounded semaglutide and tirzepatide; brand-name access runs through a separate $99/mo pathway subscription with medication billed at pharmacy rates on top
−Newer company (founded 2024) with limited long-term track record and outcome data; the 4.6/5 Trustpilot rating across 766 reviews is the strongest early evidence available
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive (replies typically within 24 hours) but less proactive than premium platforms; a $49.99/mo premium coaching add-on covers those who want higher touch

Our Verdict

Hims edges out Shed with a score of 7.9/10 vs 7.8/10. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither Hims nor Shed feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review